| Bioactivity | PCSK9-IN-20 (Compound 3i) is a PCSK9 inhibitor with an IC50 of 3.96 µM. PCSK9-IN-20 decreases PCSK9 and increases LDLR protein expression in vitro[1]. |
| Target | IC50: 3.96 µM (PCSK9) |
| Name | PCSK9-IN-20 |
| CAS | 2929219-77-0 |
| Formula | C27H32N6O5S2 |
| Molar Mass | 584.71 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhixin Ma, et al. Identification of benzothiazoles as novel PCSK9 inhibitors. Bioorg Med Chem Lett. 2023 Nov 6:129542. |
PCSK9-IN-20
CAS: 2929219-77-0 F: C27H32N6O5S2 W: 584.71
PCSK9-IN-20 (Compound 3i) is a PCSK9 inhibitor with an IC50 of 3.96 µM. PCSK9-IN-20 decreases PCSK9 and increases LDLR
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.